1. Home
  2. REPL vs SHEN Comparison

REPL vs SHEN Comparison

Compare REPL & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • SHEN
  • Stock Information
  • Founded
  • REPL 2015
  • SHEN 1902
  • Country
  • REPL United States
  • SHEN United States
  • Employees
  • REPL 331
  • SHEN N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • SHEN Telecommunications Equipment
  • Sector
  • REPL Health Care
  • SHEN Telecommunications
  • Exchange
  • REPL Nasdaq
  • SHEN Nasdaq
  • Market Cap
  • REPL 1.1B
  • SHEN 626.7M
  • IPO Year
  • REPL 2018
  • SHEN N/A
  • Fundamental
  • Price
  • REPL $13.98
  • SHEN $10.78
  • Analyst Decision
  • REPL Strong Buy
  • SHEN Strong Buy
  • Analyst Count
  • REPL 6
  • SHEN 1
  • Target Price
  • REPL $19.83
  • SHEN $26.00
  • AVG Volume (30 Days)
  • REPL 610.9K
  • SHEN 212.4K
  • Earning Date
  • REPL 02-12-2025
  • SHEN 02-20-2025
  • Dividend Yield
  • REPL N/A
  • SHEN 0.94%
  • EPS Growth
  • REPL N/A
  • SHEN 2121.97
  • EPS
  • REPL N/A
  • SHEN 3.54
  • Revenue
  • REPL N/A
  • SHEN $328,058,000.00
  • Revenue This Year
  • REPL N/A
  • SHEN $17.88
  • Revenue Next Year
  • REPL $1,065.54
  • SHEN $13.58
  • P/E Ratio
  • REPL N/A
  • SHEN $2.99
  • Revenue Growth
  • REPL N/A
  • SHEN 14.16
  • 52 Week Low
  • REPL $4.92
  • SHEN $9.77
  • 52 Week High
  • REPL $17.00
  • SHEN $21.89
  • Technical
  • Relative Strength Index (RSI)
  • REPL 55.54
  • SHEN 39.01
  • Support Level
  • REPL $13.40
  • SHEN $9.77
  • Resistance Level
  • REPL $14.59
  • SHEN $12.15
  • Average True Range (ATR)
  • REPL 0.84
  • SHEN 0.58
  • MACD
  • REPL -0.02
  • SHEN -0.00
  • Stochastic Oscillator
  • REPL 66.52
  • SHEN 42.44

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through two business units: tower and broadband. The tower segment leases company-owned cell tower spaces to other wireless communication providers, while the broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

Share on Social Networks: